PT  - JOURNAL ARTICLE
AU  - Holenya, Pavlo
AU  - Lange, Paul Joris
AU  - Reimer, Ulf
AU  - Woltersdorf, Wolfram
AU  - Panterodt, Thomas
AU  - Glas, Michael
AU  - Wasner, Mark
AU  - Eckey, Maren
AU  - Drosch, Michael
AU  - Hollidt, Jörg-Michael
AU  - Naumann, Michael
AU  - Kern, Florian
AU  - Wenschuh, Holger
AU  - Lange, Robert
AU  - Schnatbaum, Karsten
AU  - Bier, Frank F.
TI  - Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
AID  - 10.1101/2020.11.24.20216663
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.24.20216663
4099  - http://medrxiv.org/content/early/2020/11/27/2020.11.24.20216663.short
4100  - http://medrxiv.org/content/early/2020/11/27/2020.11.24.20216663.full
AB  - Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but may be a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n=24 patient samples and n=12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43 and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests.Competing Interest StatementP.H., U.R., M.E., M.D., F.K., H.W. and K.S. are employees of JPT Peptide Technologies GmbH which commercialized the peptide microarrays use in this study.Funding Statementno external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Aerztekammer Sachsen-Anhalt, Ethic votum identifier 64-20 from 24.11.2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are presented in the manuscript